Can people with resistant HIV omit NRTIs when switching from a failing regimen?
Meta-analysis shows superiority of integrase inhibitors in first-line HIV therapy and benefits for people changing treatment due to resistance
It's tough to make predictions
Australian researchers project that many HIV-positive people will run out of treatment options
Swiss research identifies factors associated with use of non-recommended HIV therapy
The generic generation
Glucose metabolism worsens in HIV treatment-experienced taking NRTI-sparing regimens
Are antiretroviral switch or simplification studies of benefit for patients?
First generic HIV drugs could save US at least $920 million a year
